Good morning, everyone. Damian Garde here, filling in for Ed Silverman with your requisite helping of headlines about the drug business. Here’s hoping they propel you into and through all that stands between you and the weekend.
The FDA’s latest approval, a drug for a symptom of Parkinson’s disease, is drawing a bit of a controversy, STAT tells us. Made by Adamas Pharmaceuticals (ADMS), the drug is an extended-release version of the generic amantadine, meant to address the involuntary spasms that sometimes result from treating Parkinson’s. But a month’s supply of regular amantadine goes for about $45, and thus Adamas’s previously disclosed plan to charge between $10,000 and $30,000 a year for its reformulated drug is already attracting criticism.